Table 1 Risk associated with various A/C regimens

From: Personalizing neoadjuvant chemotherapy regimens for triple-negative breast cancer using a biology-based digital twin

Treatment regimen

Adriamycin

Cyclophosphamide

Total dose (NU)

Toxicity (TU)

Total dose (NU)

Toxicity (TU)

4–AC–2

4

7.68 (SD = 0.78)

4

2.53 (SD = 0.24)

4–AC–3

4

7.67 (SD = 0.78)

4

2.53 (SD = 0.24)

2–AC–2

2

3.84 (SD = 0.39)

2

1.27 (SD = 0.12)

6–AC–2

6

11.52 (SD = 1.17)

6

3.80 (SD = 0.36)

  1. Schedules are formatted as: (number of cycles)–(type of chemotherapy)–(weeks between cycles)
Back to article page